Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Bilia in connection with the issuance and repurchase of bonds
Mandate

Vinge has advised Bilia in connection with the issuance and repurchase of bonds

October 09, 2018 Capital Markets and Public M&A Automotive, Mobility and Electrification

Vinge has advised Bilia AB (publ) in connection with the issue of new senior and non subordinated bonds with a framework amount of SEK 1 500 000 000 as well as the repurchase of SEK 500 000 000 of a previously issued senior and non subordinated bond with a maturity date in 2021.

Initially, a bond in the amount of SEK 800 000 000 was issued, of which SEK 500 000 000 will be used for the repurchase of the previously issued bond and the remaining amount for repayment of bank loans as well as part financing of Bilia’s acquisitions in Belgium. 

The newly issued bonds have a term of 5 years and are subject to a variable interest of STIBOR 3M + 1.40%. 

Vinge’s team primarily consisted of Anders Strid, Lina André and Henrik Wastenson (tax).
 

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

 Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026